Lynparza May Still Rival Tesaro's Niraparib In Ovarian Cancer Therapy
Executive Summary
AstraZeneca hopes "robust" data from its Phase III SOLO-2 trial will pave the way for its PARP-inhibitor Lynparza (olaparib) to be used in the US market as a maintenance therapy in BRCA-mutated second-line ovarian cancer. But some analysts think FDA may want more proof before giving the okay.
You may also be interested in...
AstraZeneca Mulls Broad Ovarian Cancer Maintenance Approval For Lynparza
Tesaro's niraparib has an advantage over other PARP inhibitors in that it has been tested successfully in Phase III for ovarian cancer patients with and without BRCA mutations, but AstraZeneca thinks it may have a case for broad labeling without pivotal data in this population.
AstraZeneca's Lynparza Looks To Hang On To Lead, With Tesaro's Niraparib On The Way
Tesaro's niraparib has an advantage over other PARP inhibitors in that it has been tested successfully in ovarian cancer patients with and without BRCA mutations, but AstraZeneca thinks it may have a case for broad labeling in this population.
Ovarian Cancer Drugs Will Get ICER Review As Olaparib's Maintenance Indication Looms
PARP inhibitors from Tesaro, Clovis, and AstraZeneca have been tentatively chosen for the evaluation.